SAB BIO Announces Oversubscribed $175 Million Private Placement
SAB BIO (Nasdaq: SABS) has secured a significant $175 million private placement with participation from strategic investor Sanofi and several prominent institutional investors. The oversubscribed financing includes the issuance of 1,000,000 shares of Series B nonvoting convertible preferred stock at a conversion price of $1.75 per share.
The company will also issue warrants that could provide up to an additional $284 million in gross proceeds if exercised in full. The proceeds will fund the pivotal Phase 2b SAFEGUARD study of SAB-142 for delaying progression of autoimmune Type 1 Diabetes (T1D) in newly diagnosed patients, extending the company's cash runway into mid-2028.
SAB BIO (Nasdaq: SABS) ha ottenuto un significativo finanziamento privato da 175 milioni di dollari con la partecipazione dell'investitore strategico Sanofi e di diversi importanti investitori istituzionali. Il finanziamento, che ha registrato un eccesso di domanda, prevede l'emissione di 1.000.000 di azioni privilegiate convertibili Serie B senza diritto di voto a un prezzo di conversione di 1,75 dollari per azione.
La societ脿 emetter脿 inoltre warrant che potrebbero generare fino a un ulteriore incasso lordo di 284 milioni di dollari se esercitati completamente. I proventi finanzieranno lo studio cruciale di Fase 2b SAFEGUARD di SAB-142, volto a ritardare la progressione del diabete autoimmune di tipo 1 (T1D) nei pazienti di nuova diagnosi, estendendo la liquidit脿 dell'azienda fino a met脿 2028.
SAB BIO (Nasdaq: SABS) ha asegurado una colocaci贸n privada significativa de 175 millones de d贸lares con la participaci贸n del inversor estrat茅gico Sanofi y varios inversores institucionales destacados. La financiaci贸n, que estuvo sobresuscrita, incluye la emisi贸n de 1,000,000 acciones preferentes convertibles Serie B sin derecho a voto a un precio de conversi贸n de 1.75 d贸lares por acci贸n.
La compa帽铆a tambi茅n emitir谩 warrants que podr铆an proporcionar hasta 284 millones de d贸lares adicionales en ingresos brutos si se ejercen en su totalidad. Los fondos se destinar谩n al estudio crucial de Fase 2b SAFEGUARD de SAB-142 para retrasar la progresi贸n de la diabetes autoinmune tipo 1 (T1D) en pacientes reci茅n diagnosticados, extendiendo la liquidez de la empresa hasta mediados de 2028.
SAB BIO (雮橃姢雼�: SABS)電� 鞝勲灥鞝� 韴瀽鞛� Sanofi鞕� 鞐煬 欤检殧 旮瓣磤 韴瀽鞛愳潣 彀胳棳搿� 1鞏� 7,500毵� 雼煬 攴滊鞚� 靷 韴瀽毳� 頇曤炒頄堨姷雼堧嫟. 齑堦臣 觳暯霅� 鞚措矆 鞛愱笀 臁半嫭鞐愲姅 欤茧嫻 鞝勴櫂 臧�瓴╈澊 1.75雼煬鞚� 鞁滊Μ歃� B 氍挫潣瓴瓣秾 鞝勴櫂 鞖办劆欤� 1,000,000欤� 氚滍枆鞚� 韽暔霅╇媹雼�.
須岇偓電� 霕愴暅 鞝勳暋 頄夓偓 鞁� 斓滊寑 2鞏� 8,400毵� 雼煬鞚� 齑� 靾橃澋鞚� 鞝滉车頃� 靾� 鞛堧姅 鞗岆煱韸鸽ゼ 氚滍枆頃� 鞓堨爼鞛呺媹雼�. 鞚� 鞛愱笀鞚� 鞁犼窚 歆勲嫧霅� 鞛愱皜氅挫棴靹� 1順� 雼闺嚚氤�(T1D) 歆勴枆 歆�鞐办潉 鞙勴暅 SAB-142鞚� 欷戩稊鞝� 2b靸� SAFEGUARD 鞐瓣惮鞐� 靷毄霅橂┌, 須岇偓鞚� 順勱笀 鞙犽彊靹膘潉 2028雲� 欷戨皹旯岇 鞐办灔鞁滍偓 瓴冹瀰雼堧嫟.
SAB BIO (Nasdaq : SABS) a obtenu un placement priv茅 important de 175 millions de dollars avec la participation de l'investisseur strat茅gique Sanofi et plusieurs investisseurs institutionnels de renom. Ce financement sursouscrit comprend l'茅mission de 1 000 000 d'actions privil茅gi茅es convertibles de s茅rie B sans droit de vote 脿 un prix de conversion de 1,75 dollar par action.
L'entreprise 茅mettra 茅galement des bons de souscription qui pourraient g茅n茅rer jusqu'脿 284 millions de dollars de recettes brutes suppl茅mentaires s'ils sont enti猫rement exerc茅s. Les fonds serviront 脿 financer l'茅tude pivot de phase 2b SAFEGUARD de SAB-142 visant 脿 retarder la progression du diab猫te auto-immun de type 1 (T1D) chez les patients nouvellement diagnostiqu茅s, prolongeant ainsi la tr茅sorerie de la soci茅t茅 jusqu'脿 mi-2028.
SAB BIO (Nasdaq: SABS) hat eine bedeutende Private Placement in H枚he von 175 Millionen US-Dollar mit Beteiligung des strategischen Investors Sanofi und mehrerer namhafter institutioneller Investoren gesichert. Die 眉berzeichnete Finanzierung umfasst die Ausgabe von 1.000.000 Aktien der Serie B nicht stimmberechtigter wandelbarer Vorzugsaktien zu einem Wandlungspreis von 1,75 US-Dollar pro Aktie.
Das Unternehmen wird au脽erdem Bezugsrechte ausgeben, die bei vollst盲ndiger Aus眉bung zus盲tzliche Bruttoerl枚se von bis zu 284 Millionen US-Dollar generieren k枚nnten. Die Mittel werden die entscheidende Phase-2b SAFEGUARD-Studie von SAB-142 zur Verz枚gerung des Fortschreitens des Autoimmun-Typ-1-Diabetes (T1D) bei neu diagnostizierten Patienten finanzieren und die Liquidit盲t des Unternehmens bis Mitte 2028 惫别谤濒盲苍驳别谤苍.
- Secured substantial $175 million in private placement funding with potential for additional $284 million from warrants
- Strong investor participation including strategic investor Sanofi and prominent institutional investors
- Cash runway extended into middle of 2028
- Funding secured to fully complete Phase 2b SAFEGUARD study
- Significant potential dilution with convertible preferred stock convertible into 100 million common shares
- Securities being offered in private placement are restricted and not registered under Securities Act
Insights
SAB BIO secures substantial $175M financing to advance T1D therapy with impressive investor lineup and extended cash runway until 2028.
SAB BIO's $175 million oversubscribed private placement represents a significant financial milestone that substantially strengthens the company's position in the autoimmune diabetes space. The participation of Sanofi as a strategic investor alongside prestigious financial institutions like RA Capital Management and Blackstone Multi-Asset Investing signals strong confidence in SAB's novel immunotherapy platform and clinical development program.
The financing structure is particularly noteworthy - SAB is issuing 1,000,000 shares of Series B nonvoting convertible preferred stock at an effective price of
Most critically, this financing fully funds the pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune Type 1 diabetes in newly diagnosed patients. By extending the cash runway into mid-2028, SAB has effectively eliminated near-term financing risk and provided clear visibility through this crucial clinical trial and potential commercialization preparation.
The impressive roster of new investors, including specialized life science funds like RA Capital, Commodore Capital, and Vivo Capital, suggests sophisticated investors see significant potential in SAB's approach to modifying the progression of T1D - a condition with few disease-modifying treatment options. The continued support from existing investors further validates the company's progress since previous funding rounds.
Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners
Proceeds expected to fully fund completion of pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune T1D in newly diagnosed T1D patients (Stage 3)
Company expects proceeds to extend cash runway into the middle of 2028
Potential for up to an additional
MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq:聽), (鈥淪AB BIO鈥� or the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying progression of autoimmune type 1 diabetes (T1D) in newly diagnosed autoimmune T1D patients, today announced that it has entered into a securities purchase agreement (the 鈥淎greement鈥�) with certain accredited and institutional investors to raise
The private placement includes participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners.
Pursuant to the terms of the Agreement, SAB BIO will issue an aggregate of up to 1,000,000 shares of the Company鈥檚 Series B nonvoting convertible preferred stock, which are convertible into up to an aggregate of 100,000,000 shares of the Company鈥檚 common stock at a conversion price of
SAB BIO intends to use the net proceeds from the private placement to fully fund the Phase 2b SAFEGUARD study of SAB-142 in Stage 3 autoimmune T1D, and for working capital and general corporate purposes. The proceeds from the private placement combined with the Company鈥檚 current cash and cash equivalents are expected to extend its cash runway into the middle of 2028.
Leerink Partners is acting as lead placement agent for the private placement. UBS Investment Bank, Chardan and Oppenheimer & Co. are acting as joint placement agents.
The securities to be issued in the financing described above are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the common shares, nor shall there be any sale of the common shares in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma, to treat and prevent immune and autoimmune disorders. The Company鈥檚 lead asset, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression. Using advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine鈩�, the only transgenic animal with a human artificial chromosome, SAB BIO鈥檚 drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, human IgGs that can address a wide range of serious unmet needs in human diseases without the need for convalescent plasma or human donors.
Forward-Looking Statements
Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as 鈥渂elieve,鈥� 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渢o be,鈥� 鈥渆stimate,鈥� 鈥渃ontinue,鈥� 鈥渁nticipate,鈥� 鈥渋ntend,鈥� 鈥渆xpect,鈥� 鈥渟hould,鈥� 鈥渨ould,鈥� 鈥減lan,鈥� 鈥減redict,鈥� 鈥減otential,鈥� 鈥渟eem,鈥� 鈥渟eek,鈥� 鈥渇uture,鈥� 鈥渙utlook,鈥� and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the Company鈥檚 expectations regarding the completion, timing and size of the private placement, the potential exercise of warrants in the private placement, the Company鈥檚 expected cash runway, the intended use of the net proceeds, and the development and clinical trial results of the Company鈥檚 T1D program and other discovery programs.
These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry鈥檚 results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned 鈥淩isk Factors鈥� in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.
CONTACTS
Media Relations:
Kaelan Hollon,
Vice President of Communications
Investor Relations:
Kevin Gardner
LifeSci Advisors
FAQ
How much funding did SAB BIO (SABS) raise in the July 2025 private placement?
Who are the major investors in SAB BIO's private placement?
What will SAB BIO use the private placement proceeds for?
How long will the funding extend SAB BIO's cash runway?
What are the terms of SAB BIO's Series B preferred stock conversion?
